🧵 1. Glenmark Pharma's Q1 profit surges to Rs 340.27 crore, up 127.0%. Revenue at Rs 3244.19 crore, driven by demand for drugs and lower costs. #business
🧵 1. Glenmark Pharma's Q1 profit surges to Rs 340.27 crore, up 127.0%. Revenue at Rs 3244.19 crore, driven by demand for drugs and lower costs. #business
🧵 2. EBITDA at Rs 588.3 crore, up 34.5% YoY. One-time charge of Rs 52.02 crore for repairs in previous year. R&D expenses at 7.4% of sales.
🧵 3. Glenmark CEO, Glenn Saldanha, confident of meeting FY25 goals with strong revenue growth in key regions and focus on innovative products.
🧵 4. India sales up by 11.9%, North America up by 3.3% QoQ. Europe operations show growth as Glenmark Pharmaceuticals Ltd reports positive Q1 performance.
🧵 5. Company remains committed to launching new products like Envafolimab and Winlevi®, aiming to achieve high double-digit market shares globally.
🧵 Read more at: https://www.financialexpress.com/business/industry-glenmark-pharma-records-surge-in-q1-profit-at-rs-340-27-crore-on-strong-demand-cmd-says-confident-of-meeting-fy25-objectives-3583633/